On August 31, 2022 Veracyte, Inc. (Nasdaq: VCYT) reported that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, taking place September 9-13, 2022, in Paris (Press release, Veracyte, AUG 31, 2022, View Source [SID1234618822]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The abstracts we’ll share at ESMO (Free ESMO Whitepaper) 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients," said Marc Stapley, Veracyte’s chief executive officer. "We are particularly excited about new data from a post-hoc analysis that evaluated the clinical performance of our Decipher Prostate test in one arm of the large, multi-center, randomized STAMPEDE trial. We believe these data may help expand the Decipher test’s availability to advanced prostate cancer patients in the United States, and also support our plans to offer the Decipher Prostate test as an IVD on the nCounter Analysis System for use outside of the United States where laboratories can perform it locally."
Following are details of the abstracts that will be shared as part of the ESMO (Free ESMO Whitepaper) 2022 Congress: